

Co-organisers:



Supporting Organisations:



# Healthcare Innovation and Technology Summit

14 October 2022



Charles K. Kao Auditorium  
Hong Kong Science Park





## Summit Overview

**Healthcare Innovation and Technology Summit 2022 (HITS 2022)** brings together global innovation and healthcare leaders, and young talents for knowledge transfer and exchange amongst the **BIG QUESTIONS** and **BIG PERSPECTIVES** that hit you.

- Co-organised by the Faculty of Medicine of The Chinese University of Hong Kong (CU Medicine) and Hong Kong Science and Technology Parks Corporation (HKSTP), and in celebration of CU Medicine's 40th Anniversary and HKSTP's 20th Anniversary.
- Stage some of the most influential speakers in healthcare and innovation.
- Showcase R&D success stories and remarkable outcomes in Hong Kong.
- Provide opportunities for talents and investors in both start-up businesses and established projects.

## Highlights

- A comprehensive and innovative programme: Panel discussions covering Successful Translational Research Projects, Intellectual Property & Patent Protection for InnoHealth, Opportunities & Challenges in Cancer Management, Healthcare Innovation & Investment Opportunities in Start-ups, CU Medicine & HKSTP's Strategies and Resources in Nurturing Young Talents.
- Heavyweight moderators and speakers: Meet and connect with the thought-provoking leaders in healthcare and innovation.
- Guided tours to CUHK's InnoHK Centres and HKSTP's Experience Centre.
- Exhibition of CUHK's InnoHK Centres, and companies and start-ups in pharmaceuticals, medical devices, healthcare and technology: Chat with the aspiring entrepreneurs and explore collaboration.



## About Faculty of Medicine, The Chinese University of Hong Kong

Since the establishment in 1981, the Faculty of Medicine of The Chinese University of Hong Kong (CU Medicine) has always been committed to making a difference to the world by improving people's health through advancing health care, medical education and research.

At the heart of CU Medicine, it is our motto "Transforming Our Passion into Perfection", which highlights our determination to strive for the best to benefit patients and society at large.

It is our mission to empower tomorrow's leading physicians and scientists by giving our students rewarding and fruitful learning experiences. With the accelerated pace of changes in the 21st Century, our students are nurtured to meet the local, national and international healthcare challenges through a well-designed curriculum, mentored by teams of brilliant teachers, exposed to unlimited opportunities of international learning, innovative research and compassionate community service.

Over the years, we have made notable scientific achievements that had tangible impacts on how the world understands and treats diseases. Our Faculty members work across disciplines with international experts and have made collaborative discoveries which have changed the global clinical practice and shifting treatment paradigms in cancer therapies, digestive and metabolic diseases. The Faculty is at the forefront of the clinical application of genomics and our researchers are the ones who developed the robust non-invasive prenatal test for Down syndrome. We have achieved regional and world firsts in many research and procedures and gained a reputation as a pioneer in some of the world's most advanced surgical technologies and techniques including robotics and minimally invasive surgery.

For more information about CU Medicine, please visit [www.med.cuhk.edu.hk](http://www.med.cuhk.edu.hk).





## About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) has for 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong's leading R&D hub with over 11,000 research professionals and over 1,100 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of the Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong's international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at [www.hkstp.org](http://www.hkstp.org).



Time	Programme
09:00 – 9:25	<p><b>Opening Session</b></p> <p><b>Welcome Remarks</b></p> <p><b>Professor Francis CHAN, SBS, JP</b> Dean, Faculty of Medicine, The Chinese University of Hong Kong</p> <p><b>Welcome Remarks</b></p> <p><b>Mr. Albert WONG</b> Chief Executive Officer Hong Kong Science and Technology Parks Corporation</p> <p><b>Opening Address</b></p> <p><b>Professor the Honourable SUN Dong, JP</b> Secretary for Innovation, Technology and Industry Government of the Hong Kong Special Administrative Region</p>
09:25 – 09:40	<p><b>Unleashing the Potential of Scientific Discoveries and Inventions: How Government and University Policies Affect Commercialisation Plans?</b></p> <p><b>Professor Dennis LO, SBS, JP</b> Founding Scientific Director, Centre for Novostics</p> <p><b>Abstract:</b></p> <p>My group has worked on the diagnostic applications of cell-free DNA in plasma since 1997. Since then, we have commercialised a number of molecular diagnostic tests, including non-invasive prenatal tests (NIPTs), a multi-cancer early detection (MCED) and a screening test for nasopharyngeal carcinoma (NPC). In this talk, I shall discuss first-hand experience about how government and university policies had affected our knowledge transfer experience in this journey spanning 25 years. In particular, certain policies, while seemingly ‘well established’ might occasionally have adverse impact lasting over a decade.</p>

Time	Programme
09:40 – 09:55	<p><b>Human-Machine Collaboration in Surgical Applications</b></p> <p><b>Professor Russell TAYLOR</b>            Director of the Laboratory for Computational Sensing and Robotics,            Johns Hopkins University</p> <p><b>Abstract:</b></p> <p>This talk will discuss an emerging three-way partnership between physicians, technology, and information to improve treatment processes. Computer-integrated interventional medicine (CIIM) systems combine innovative algorithms, robotic devices, imaging systems, sensors, and human-machine interfaces to work cooperatively with surgeons in the planning and execution of surgery and other interventional procedures. Two crucial issues in managing this partnership are 1) how can the human physician specify what the robot is to do and 2) how can the computer controlling the robot ensure that the robot performs the specified task correctly and safely. This talk will discuss several common paradigms for approaching these questions and will illustrate the approaches with examples drawn from our past and current work.</p>
09:55 – 10:25	<p><b>Translational Research: From Concepts into Healthcare Innovation (Session I)</b></p> <p><b>Moderators:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Francis CHAN, SBS, JP</b>            Dean, Faculty of Medicine, The Chinese University of Hong Kong</li> <li>• <b>Professor Patrick YUNG, MH, JP</b>            Director, Centre for Neuromusculoskeletal Restorative Medicine</li> </ul> <p><b>Panellists:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Dennis LO, SBS, JP</b>            Founding Scientific Director, Centre for Novostics</li> <li>• <b>Professor Siew NG</b>, Director, Microbiota I-Center</li> <li>• <b>Professor Russell TAYLOR</b>, Director of the Laboratory for Computational Sensing and Robotics, Johns Hopkins University</li> </ul>
10:25 – 10:40	<b>Networking Break / Exhibition</b>



Time	Programme
10:40 – 10:55	<p><b>How to Protect Your Intellectual Property in Product Development, Commercialisation and Fund Raising? An Engineer Entrepreneur Perspective</b></p> <p><b>Professor Samuel AU</b> Director, Multi-Scale Medical Robotics Center</p> <p><b>Abstract:</b> Intellectual property (IP) is a valuable asset for start-ups. IP needs to be sufficiently protected from duplication as it can threaten the market position of an organisation. However, IP protections can also be inefficient, distracting, and easily hinder innovation, particularly in a start-up company setting with limited resources. In this talk, Dr. Au will share his experience in IP protection through his start-up journey. Particularly, he will talk about the unique challenges of IP protection on multi-disciplinary and complex technology in medical robotics industry. He will discuss the essence of agility and domain knowledge and how these elements help an organisation to effectively carry out IP protections without hindering true innovation.</p>
10:55 – 11:10	<p><b>Strategic Approach to IP Protection for Biomedical Innovations in GBA and China</b></p> <p><b>Ms. Jennifer CHE</b> Vice President and Principal, Eagle IP Limited</p> <p><b>Abstract:</b> Ms. Jennifer CHE, J.D., Vice President and Principal of Eagle IP Limited, will share about the unique IP challenges biomedical innovations in the GBA and China face. She'll demonstrate how a strategic approach to IP is crucial - especially at the earliest stages - to avoiding messy issues down the road. She will finally touch upon what unique role Hong Kong can play to help protect and cultivate future important biomedical inventions arising out of the GBA and China.</p>
11:10 – 11:40	<p><b>Intellectual Property and Patent Protection for InnoHealth</b></p> <p><b>Moderators:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Dennis LO, SBS, JP</b> Founding Scientific Director, Centre for Novostics</li> <li>• <b>Professor Justin WU</b>, Associate Dean (Health Systems), Faculty of Medicine, The Chinese University of Hong Kong</li> </ul> <p><b>Panellists:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Samuel AU</b>, Director, Multi-Scale Medical Robotics Center</li> <li>• <b>Ms. Jennifer CHE</b>, Vice President and Principal, Eagle IP Limited</li> <li>• <b>Professor Benny ZEE</b>, Director, Office of Research and Knowledge Transfer Services, The Chinese University of Hong Kong</li> </ul>

Time	Programme
11:40 – 11:55	<p><b>Disruptive Innovations in Cancer Care</b></p> <p><b>Professor Tony MOK, BBS</b> Chairman, Department of Clinical Oncology The Chinese University of Hong Kong</p> <p><b>Abstract:</b> Cancer has been the major cause of death for mankind in the past century. For decades, the main modalities that we can offer patients were nothing but surgery, radiation and cytotoxic chemotherapy. Only in the past 15 years, significant advances in molecular targeted therapy and immunotherapy have helped to reduce mortality of few common malignancies such as lung and liver cancer. A number of upcoming disruptive innovations may move cancer care to next stage. For prevention and early detection, combination of AI assisted imaging and plasma cfDNA hold the promise of detecting early stage cancer. In addition, concept of immune modulation as a method of chemoprevention is being developed. To improve chance of cure, disruptive concepts such as peri-operative immunotherapy and detection of minimal residual disease are under intense investigation. As for advanced stage disease, main objective is to target the targetable and to improve long term survival. Antibody drug conjugate, epigenetic inhibition, cellular therapy and cancer vaccine are the upcoming treatment holding the promise to revolutionise cancer care.</p>
11:55 – 12:10	<p><b>Globalisation of Cancer Care: Moving to Pre-emptive Cancer Detection</b> (Pre-recorded video)</p> <p><b>Professor the Lord DARZI of Denham OM KBE PC FRS</b> Co-Director of the Institute of Global Health Innovation and Paul Hamlyn Chair of Surgery, Imperial College London</p> <p><b>Abstract:</b> Approximately half of all cancers are diagnosed late. Early detection of cancers through traditional screening programmes has poor uptake and fail to detect more aggressive forms of cancers. Recent innovations in early detection blood tests for cancers offers promise. Lord Darzi will talk about the concept of pre-emptive health and how innovations across biotechnology and artificial intelligence is paving the way for advances in cancer care and prevention.</p>



Time	Programme
12:10 – 12:40	<p><b>Opportunities and Challenges in Cancer Management: From Research to Clinical Application</b></p> <p><b>Moderators:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Anthony CHAN</b>, Pro-Vice-Chancellor/Vice-President, Li Shu Fan Medical Foundation Professor of Clinical Oncology, The Chinese University of Hong Kong</li> <li>• <b>Professor Stephen CHAN</b>, Ip's Family Trust Professor in Clinical Oncology, The Chinese University of Hong Kong</li> </ul> <p><b>Panellists:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Tony MOK, BBS</b>, Chairman, Department of Clinical Oncology, The Chinese University of Hong Kong</li> <li>• <b>Professor YU Jun</b>, Director, Institute of Digestive Disease, The Chinese University of Hong Kong</li> </ul>
12:40 – 14:00	<p><b>Lunch / Guided Tour to InnoHK Centres and Experience Centre / Exhibition</b></p>
14:00 – 14:15	<p><b>Scientists as Entrepreneurs</b></p> <p><b>Dr. Shawn LEUNG</b>            Founder, Chairman and Chief Executive Officer            SinoMab BioScience Limited</p> <p><b>Abstract:</b></p> <p>A historical review of biotechnology development has revealed the different factors needed for the creation of a permission environment leading to a full-blown industry. I will share my humble experience with scientists interested in becoming bioentrepreneurs, and discuss the different elements required, in addition to the technological push and a market pull, for starting a biotech venture here in Hong Kong, especially with the support from HKSTP. For the less ambitious scientists, there are different career opportunities available, from working in the lab as a bench scientist, to working as an analyst for biotech ventures.</p>

Time	Programme
------	-----------

14:15 – 14:30

### Challenges Encountered by Biomedical Technology Entrepreneurs

**Dr. Aldrin YIM**

Founder and Chief Executive Officer, Codex Genetics Limited

**Abstract:**

It is important to have a startup that aligns with our purpose of life. I am always curious about living beings. I find it fascinating that organisms can evolve, and that all the molecules within our body get synchronised and uniquely define us as human. This drives me to my PhD study in medicine and has led me to many clinical cases that I believe we could solve, not only as a scientist but also as an entrepreneur. Behind every clinical case is a family in distress, and it is their stories that power us through the crazy journey in biotech startup, which is a fascinating and humbling experience. I hope our story can inspire you for your startup journey.

14:30 – 15:00

### A Pioneering Role of HKSTP in Nurturing Young Talents

**Moderators:**

- Mr. Albert WONG, Chief Executive Officer  
Hong Kong Science and Technology Parks Corporation
- Dr. Grace LAU, Head of Institute of Translational Research,  
Hong Kong Science and Technology Parks Corporation

**Panellists:**

- Dr. Shawn LEUNG, Founder, Chairman and Chief Executive Officer, SinoMab BioScience Limited
- Dr. Aldrin YIM, Founder and Chief Executive Officer, Codex Genetics Limited
- Dr. Allen YU, Founder and Chief Technology Officer, Codex Genetics Limited



Time	Programme
15:00 – 15:15	<p><b>To Grow and Flourish a Start-up Company</b></p> <p><b>Mr. Stanley SY</b> Chairman, Hong Kong Regen Medtech Limited</p> <p><b>Abstract:</b></p> <p>In the last decade, Hong Kong has been rapidly growing as an innovative start-up hub. Specifically, with government support and policy changes, there has been a big portion of growth in the biotechnology and healthcare sector. There is an increasing interest in many young talents to build their own businesses and turn to the start-up route. The life cycle of a start-up is very turbulent and even more so for biotechnology and healthcare heavy start-ups. Many often underestimate the difficulties of technology adoption within healthcare and the need to continually grow and scale in our market today. Coming from a strong biotechnology background, Stanley SY graduated from The Chinese University of Hong Kong with a master's degree in Biomedical Engineering and has been actively involved in the Hong Kong Biotechnology scene for more than a decade. He brings to the discussion his first-hand experience of running and growing his start up, Sanomics and Hong Kong Regen Medtech and his advice to the younger generation on how to grow their own start up.</p>
15:15 – 15:30	<p><b>Launching a MedTech Start-up from ETH Zürich – The Success and Challenges</b></p> <p><b>Professor Bradley NELSON</b> Professor of Robotics and Intelligent Systems, ETH Zürich</p> <p><b>Abstract:</b></p> <p>The Swiss Federal Council lists six main purposes for Switzerland's two federal universities and four government laboratories. One of these purposes is "exploit their research findings," and start-up companies are strongly encouraged in order to translate technology out of the labs and into Swiss society. My Multi-Scale Robotics Lab at ETH Zurich has spun-off a number of companies over the years, four of which fall in the medtech space. I will discuss the the challenges we have faced, the lessons learned, and what I think are the key factors in developing successful start-ups.</p>

Time	Programme
15:30 – 16:00	<p><b>Translational Research: From Concepts into Healthcare Innovation (Session II)</b></p> <p><b>Moderators:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Philip CHIU</b> Director, Multi-Scale Medical Robotics Center</li> <li>• <b>Dr. Owen KO</b>, Assistant Dean (Research), Faculty of Medicine, The Chinese University of Hong Kong</li> </ul> <p><b>Panellists:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Bradley NELSON</b>, Professor of Robotics and Intelligent Systems, ETH Zürich</li> <li>• <b>Mr. Stanley SY</b>, Chairman, Hong Kong Regen Medtech Limited</li> </ul>
16:00 – 16:15	<p><b>What Do Investors Look For?</b></p> <p><b>The Honourable Duncan CHIU</b> Legislative Council Member, Technology and Innovation Constituency</p> <p><b>Abstract:</b></p> <p>Duncan offers insights into selecting the financial partners for your start-up's needs. After a brief introduction of Hong Kong's present innovation and technology ecosystem, he will explain the role of an investor, the difference and recent trends between 'public money' and private money'. Through a case study of venture capital co-founded by Duncan, he will also discuss the critical components of successful pitching to investors and offer guidance on the best practices and common mistakes. Young entrepreneurs may learn to evaluate and present their business ideas from an investor perspective hence optimising opportunities.</p>
16:15 – 16:30	<p><b>Investment in Start-up Companies</b></p> <p><b>Moderators:</b></p> <ul style="list-style-type: none"> <li>• <b>Professor Allen CHAN</b>, Deputy Scientific Director, Centre for Novostics</li> <li>• <b>Professor Siew NG</b>, Director, Microbiota I-Center</li> </ul> <p><b>Panellists:</b></p> <ul style="list-style-type: none"> <li>• <b>The Honourable Duncan CHIU</b>, Legislative Council Member, Technology and Innovation Constituency</li> <li>• <b>Dr. Melvin TOH</b>, Vice President &amp; Chief Scientific Officer, CK Life Sciences Int'l, Inc.</li> </ul>

Time	Programme
16:30 – 17:00	<p><b>CU Medicine x HKSTP: Translating Healthcare Innovation from Science to Clinical Practice</b></p> <p><b>Perspective from CU Medicine</b></p> <p><b>Professor Francis CHAN, SBS, JP</b> Dean, Faculty of Medicine The Chinese University of Hong Kong</p> <p><b>Perspective from Hong Kong Science &amp; Technology Parks Corporation</b></p> <p><b>Mr. Albert WONG</b>, Chief Executive Officer, Hong Kong Science and Technology Parks Corporation</p>
17:15 – 18:15	<p><b>Guided Tour to InnoHK Centres and Experience Centre / Exhibition</b></p>





## Moderators and Speakers



### Professor the Honourable SUN Dong, JP

Secretary for Innovation, Technology and Industry  
Government of the Hong Kong Special Administrative Region

Professor Dong SUN is appointed Secretary for Innovation, Technology and Industry on 1 July 2022.

Professor SUN is a world-renowned scholar and scientist. He is a pioneer in robotic manipulation of biological cells and robot control. His research has led to breakthroughs in the use of robotics combined with various micro-engineering tools. He has also received numerous awards.

Professor SUN was elected as Fellow of Canadian Academy of Engineering, Member of the European Academy of Sciences and Arts, Fellow of the International Academy of Medical and Biological Engineering, and Fellow of IEEE.

Prior to his appointment, Professor SUN was the Chair Professor and Head of the Department of Biomedical Engineering at City University of Hong Kong, and the Legislative Council Member (Election Committee).



### Professor Francis CHAN, SBS, JP

Dean, Faculty of Medicine  
Choh-Ming Li Professor of Medicine and Therapeutics  
The Chinese University of Hong Kong

Professor Francis CHAN, SBS, JP, a world-renowned clinician-scientist in gastrointestinal diseases, is Choh-Ming Li Professor of Medicine and Therapeutics and Dean of Faculty of Medicine of The Chinese University of Hong Kong (CUHK). He serves as a senior associate editor of a leading international journal, Board Member of the Hospital Authority, and co-director of the Microbiota I-Center (MagIC) established under the Innovation and Technology Commission. Professor CHAN has led large-scale, multi-centered drug trials of international pharmaceutical companies. In 2019, Professor CHAN co-founded a microbiota start-up company, GenieBiome Company Limited, to transform scientific innovations into clinical applications. Currently, he is the non-executive Chairman of Board of Directors and Scientific Advisor of the Company.



### Mr. Albert WONG

Chief Executive Officer  
Hong Kong Science and Technology Parks Corporation

As HKSTP's CEO since 2016, Albert leads the team on a mission to support and grow tech ventures in the city's largest R&D hub of 11,000+ professionals and 1,100 companies, with a focus on commercialising R&D into successful innovation with impact. Through 30+ years of commercial, industrial and leadership roles with various multinationals including GE Oil & Gas China and GE Industrial Solutions Asia Pacific, he has accumulated insight and critical understanding of building companies, investment networks and solving market needs. Albert holds an Engineering Degree from HKU and an MBA from CUHK.



### Professor Samuel AU

Director  
Multi-Scale Medical Robotics Center

Professor AU Kwok Wai Samuel received the Ph.D. degree in mechanical engineering from MIT in 2007. He is currently a Professor with the Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong and the Founding Director of Multi-Scale Medical Robotics Center, InnoHK. Professor AU is also the president of Cornerstone Robotics that he found in September 2019. Before joining CUHK, he was a manager of Systems Analysis at Intuitive Surgical. He co-invented the FDA approved da Vinci Single-Site platform and was also a founding team member for the da Vinci ION system. Professor AU co-authored over 17 granted US patents/EP.



## Moderators and Speakers



### Professor Allen CHAN

Deputy Scientific Director  
Centre for Novostics

Professor Allen CHAN is Professor of Chemical Pathology at The Chinese University of Hong Kong. He is a co-inventor of the noninvasive prenatal test for Down syndrome and has pioneered the use of liquid biopsy for cancer screening. He is listed as one of the Top 20 Translational Researcher of the World by Nature Biotechnology in 2020 based on the number of granted patents. Professor CHAN is also an entrepreneur, having cofounded several biotechnology companies with Professors Dennis LO and Rossa CHIU.



### Professor Anthony CHAN

Pro-Vice-Chancellor/Vice-President  
Li Shu Fan Medical Foundation Professor of Clinical Oncology  
The Chinese University of Hong Kong

Professor Anthony CHAN is currently Pro-Vice-Chancellor/Vice-President of The Chinese University of Hong Kong, Li Shu Fan Medical Foundation Professor of Clinical Oncology, Director of the Sir YK Pao Centre for Cancer, Director of Hong Kong Cancer Institute, Chief Director of Phase 1 Clinical Trial Centre, Associate Director of State Key Laboratory for Translational Oncology (CUHK), and Master of Wu Yee Sun College.

Professor CHAN conducted pivotal studies defining new treatment standards for multimodality approaches to nasopharynx cancer, developed the clinical applications of the biomarker EBV DNA and pioneered the development of immunotherapeutic and targeted therapeutics for this disease. He has published extensively in international journals and delivered hundreds of international lectures. He has served on the Editorial Board of Journal of Clinical Oncology and has been Associate Editor of Annals of Oncology since 2014.



### Professor Stephen CHAN

Ip's Family Trust Professor in Clinical Oncology  
The Chinese University of Hong Kong

Professor Stephen Lam CHAN is the Clinical Professor at the Department of Clinical Oncology of The Chinese University of Hong Kong. His main interest of research is clinical and translational studies on hepatobiliary-pancreatic and neuroendocrine cancers. Professor CHAN has published over 160 papers in peer reviewer journals and delivered over 100 international lectures.

Internationally, Professor CHAN is serving as the Chairman of Education Committee of the International Liver Cancer Association (ILCA). He has also served in Scientific Steering Committee of the European Society for Medical Oncology Congress as a track chair in 2021 and committee member from 2022-2023. Besides, He has been invited to be Associate Editors in several journals including Journal of Hepatology, Liver Cancer, and Therapeutic Advances in Medical Oncology.

Locally, Professor CHAN is the Panel Member of Biology and Medicine Panel for the General Research Fund in Hong Kong. He has also established a charity hand in hand cancer foundation to serve patients in need.



### Ms. Jennifer CHE

Vice President and Principal  
Eagle IP Limited

Ms. Jennifer CHE is Vice President and Principal at Eagle IP and a US Patent Attorney. She has a deep understanding of the biopharmaceutical industry, having worked as a chemist, executive, and patent attorney over her 20+ year career. Jennifer spent over 10 years at Vertex Pharmaceuticals (USD70 billion S&P500 company) in Boston before joining the start-up world, most notably as head of IP at Axcella Therapeutics (a Flagship company). Jennifer moved to Hong Kong in 2017 and has been at Eagle IP for over four years. Jennifer holds a chemistry degree from MIT and a Juris Doctor (JD) from Suffolk Law in Boston.





## The Honourable Duncan CHIU

Legislative Council Member  
Technology & Innovation Constituency

Mr. Duncan CHIU has committed to technology and innovation development for nearly 20 years. He is not only a tech entrepreneur but also a veteran investor, as well as an influential advocate of local I&T policies. He often speaks at forums and conferences to promote start-up culture and helps young entrepreneurs with workshops and mentorship.

Duncan is the President of the Hong Kong Information Technology Joint Council (HKITJC) and the Convenor of Innovate for Future, a think tank representing some of the leading technology start-ups in Hong Kong. He is also a Non-official Member of the Digital Economy Development Committee, the Chairman of HKTDC Information & Communications Technology (ICT) Services Advisory Committee and the Chairman of Information Technology Services Committee of the Hospital Authority.



## Professor Philip CHIU

Director  
Multi-Scale Medical Robotics Center

Professor Philip CHIU is Director of Multi-Scale Medical Robotics Center, Professor and Chief of Upper GI and Metabolic Surgery, Department of Surgery, The Chinese University of Hong Kong.

Working at the forefront of endoscopic, minimally invasive and robotic surgery, Professor CHIU has pioneered and fostered clinical translation of many endoscopic and robotic innovations. He was the first in Hong Kong to perform ESD for treatment of early GI cancers in 2004, POEM in 2010, followed by the world's first robotic gastric ESD and colorectal ESD in 2011 and 2020 respectively. He has published over 370 peer reviewed manuscripts and earned numerous accolades including the State Scientific Technology and Progress Award from People's Republic of China.



## Professor the Lord DARZI of Denham OM KBE PC FRS

Co-Director of the Institute of Global Health Innovation and Paul Hamlyn Chair of Surgery  
Imperial College London

Professor DARZI is Co-Director of the Institute of Global Health Innovation and Paul Hamlyn Chair of Surgery at Imperial College London. He is Consultant Surgeon at Imperial College NHS Trust and the Royal Marsden NHS Foundation Trust and Chair of the Pre-emptive Medicine and Health Security Initiative at Flagship Pioneering.

In 2002, he was knighted for his services in medicine and surgery, and introduced to the United Kingdom's House of Lords as Professor the Lord DARZI of Denham in 2007. He has been a member of the Privy Council since 2009 and was awarded the Order of Merit in 2016.



## Dr. Owen KO

Assistant Dean (Research)  
Faculty of Medicine  
The Chinese University of Hong Kong

Dr. Owen KO holds Bachelor of Medical Sciences (BMedSci), Bachelor of Medicine and Bachelor of Surgery (MBChB) from The Chinese University of Hong Kong (CUHK). He pursued PhD in neuroscience at University College London in the UK and won a runner-up award of the 2014 Eppendorf & Science Prize for Neurobiology based on his PhD works. Owen currently serves as a faculty member jointly appointed by the Department of Medicine and Therapeutics & School of Biomedical Sciences at CUHK, and a principal investigator at the Li Ka Shing Institute of Health Sciences. Leading a team with expertise in biology, chemistry and engineering, his research works focus on (i) gliovascular dysfunction in neurodegeneration and (ii) the development of new imaging tools for systems and translational neuroscience. His team's recent research works have been recognised and supported by a 2020 Croucher Innovation Award, and a 2021 Excellent Young Scientists Fund from the National Natural Science Foundation of China.



## Moderators and Speakers



### Dr. Grace LAU

Head of Institute for Translational Research  
Hong Kong Science and Technology Parks Corporation

Professor DABEJ is the Director of the Institute of Global Health Innovation and Paul Ham

In her role as Head of Institute for Translational Research in Hong Kong Science Park, Grace together with her team are responsible to drive transformation in healthcare by expediting the translation of innovative biomedical technologies to benefit patients and our society, establishing Hong Kong as a preeminent hub for biomedical innovation, product development and commercialization.

Grace is an all round professional and leader in the biopharma industry with over 20 years' experience and expertise spanning across clinical research, regulatory affairs, sales and marketing and general management responsibilities in different market environment and geographic locations.

Prior to joining the pharmaceutical industry, Grace was an academic staff of The Chinese University of Hong Kong, and a guest lecturer for a number of other local and overseas institutions of higher education.



### Dr. Shawn LEUNG

Founder, Chairman and Chief Executive Officer  
SinoMab BioScience Limited

Dr. LEUNG is the Founder, Chairman and Chief Executive Officer of SinoMab BioScience Limited. Currently, he is also a Member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited and a Non-official Director of the Hong Kong Genome Institute.

Dr. LEUNG has over 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. He was the first scientist who successfully developed humanised anti-CD22 antibody and introduced the concept of "Functional Humanisation". Dr. LEUNG currently also serves as an Adjunct Professor at The Hong Kong University of Science and Technology, The Army Medical University (formerly known as the Third Military Medical University) and The Air Force Medical University (formerly known as the Fourth Military Medical University) in Mainland China. He also held positions as the Executive Director of a leading US antibody-drug conjugate company, the Managing Director of The Hong Kong Institute of Biotechnology Limited, as well as the Adjunct Professor at Fudan University and The Chinese University of Hong Kong.

Dr. LEUNG obtained his BSc and Mphil in biochemistry, as well as EMBA from CUHK. He earned his D.Phil. in molecular biology from the University of Oxford in the UK in May 1989. He was also a postdoctoral fellow at Yale University in the US from July 1989 to June 1991.



### Professor Dennis LO, SBS, JP

Founding Scientific Director  
Centre for Novostics

Professor Dennis LO is the Associate Dean (Research) of the Faculty of Medicine of The Chinese University of Hong Kong, and the Founding Scientific Director of the Centre for Novostics under the InnoHK scheme. Professor LO discovered the presence of cell-free fetal DNA in maternal blood in 1997. He has spearheaded the development of non-invasive prenatal testing (NIPT) which is now used worldwide. He has also pioneered technologies for the detection of cancer using peripheral blood. His technologies have underpinned recently launched tests for multi-cancer early detection (MCED). He has won numerous awards, including the Breakthrough Prize (2021).





### Professor Tony MOK, BBS

Chairman, Department of Clinical Oncology  
The Chinese University of Hong Kong

Professor Tony MOK is Chairman of ACT Genomics, Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. He is leading Investigator of multiple randomised studies including IPASS, AURA3, IMPRESS, KEYNOTE 042, FASTACT 2, ARCHER 1050, ALEX and PROFILE 1014.

His work was recognised by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul Bunn Jr Scientific Award in 2017, National Science and Technology Progress Award in 2017, CSCO Annual Achievement Award in 2017, ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award, Giant of Cancer Care 2020 and SingTao Hong Kong Leader of the Year 2020 Award. His is one of the "Highly Cited Researchers" by Clarivate Analytics for four consecutive years from 2018 to 2021.



### Professor Bradley NELSON

Professor of Robotics and Intelligent Systems  
ETH Zürich

Professor Brad NELSON received the B.S. degree in Mechanical Engineering from the University of Illinois at Urbana-Champaign in 1984, the M.S. degree in Mechanical Engineering from the University of Minnesota in 1987, and the Ph.D. degree in Robotics from the School of Computer Science, Carnegie-Mellon University, Pittsburgh, PA, in 1995. He has been the Professor of Robotics and Intelligent Systems at ETH Zürich since 2002, where his research focuses on micro and nanorobotics with applications in biology and medicine. He has received a number of awards for his work in robotics, nanotechnology, and biomedicine.



### Professor Siew NG

Director  
Microbiota I-Center

Professor Siew NG is Director of the Microbiota I-Center (MagIC), Assistant Dean (Development) and Professor at the Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong. She is also Scientific co-founder of GenieBiome Limited. She is a world-leading pioneer in research in inflammatory bowel disease, human gut microbiota and fecal microbiota transplantation. As an entrepreneur-scientist, her work aims to translate microbiome knowledge to novel diagnostic and therapeutic innovations to improve human health. She has published over 310 papers and was awarded Women of Power by Prestige in 2021 and Highly-cited researchers by Clarivate in 2020 and 2021.




### Mr. Stanley SY

Chairman  
Hong Kong Regen Medtech Limited

Mr. SY Ming Yiu, is the Chairman of Hong Kong Regen Medtech Limited. He obtained his B.Eng in Electronic Engineering (Biomedical engineering) and M.Phil in Electronic Engineering (Biomedical Engineering) from The Chinese University of Hong Kong. Stanley had participated in the establishment of various enterprises and has extensive experience in business operation and management of the Biotechnology Companies. His experience and expertise over the years has enabled him to be a prudent and an inspiring leader, supervise all strategic and business aspects of the company. He is appointed as a member of various government committees and since October 2018. Stanley received the HKSFC License 9 and the designation of Certified Clinical Research Associate in 2022.



## Moderators and Speakers



### Professor Russell TAYLOR

Director of the Laboratory for Computational Sensing and Robotics  
Johns Hopkins University

Professor Russell H. TAYLOR has over 30 years' experience in medical robotics and over 40 in robotics research. He received his Ph.D. in Computer Science from Stanford in 1976. After spending 1976 to 1995 as a Research Staff Member and research manager at IBM Research, he moved to Johns Hopkins University in 1995, where he is the John C. Malone Professor of Computer Science with joint appointments in Mechanical Engineering, Radiology, and Surgery and Director of the Laboratory for Computational Sensing and Robotics (LCSR). He is the author of over 550 peer-reviewed journal and conference publications and 91 patents and has received numerous awards and honors, including (most recently) election to the National Academy of Engineering.



### Dr. Melvin TOH

Vice President and Chief Scientific Officer  
CK Life Sciences Int'l., Inc.

Dr. TOH is the Vice President and Chief Scientific Officer of CK Life Sciences, which is engaged in the R&D, commercialisation of, and investment in, healthcare and agriculture-related products.

He has held various management and scientific positions in Big Pharma, biotechnology and CRO companies. Prior to joining CK Life Sciences, he managed a team of scientists at Pfizer in the United States, working on the clinical development of new cancer therapies. He was also the head and medical director of one of Pfizer's early phase research units and has been the principal investigator of many first-in-human and other clinical trials.



### Professor Justin WU

Associate Professor (Health Systems)  
Faculty of Medicine  
The Chinese University of Hong Kong

Professor WU is the Associate Dean (Health Systems) of Faculty of Medicine of The Chinese University of Hong Kong (CUHK), the Chairman of CUHK Medical Services, and the President of Asian Pacific Association of Gastroenterology. He is the former Chief Operating Officer of CUHK Medical Centre, the private teaching hospital of CUHK. In medical education, Professor WU is the founding director of Asia's first "Global Physician-Leadership Stream" (GPS), which has been the top undergraduate programme in Hong Kong since its inception in 2013. In the field of medical innovation, he is serving as director and advisor of biomedical technology companies and investment funds in Hong Kong.



### Dr. Aldrin YIM

Founder and Chief Executive Officer  
Codex Genetics Limited

Dr. Aldrin YIM is the founding CEO of Codex Genetics, with the mission to provide clinically actionable decisions through the generation of deep patient profiles. Aldrin is a neuroscientist, and received his Ph.D. at the Washington University School of Medicine. Through advanced genomics profiling approaches, Aldrin's research work has revealed important molecular insights in neuropathies such as ALS. Aldrin has played an active role in accelerating the diagnosis of rare neurological disorders in HK. He was awarded the Spirit of Hong Kong Award in 2019 in recognition of his contribution to rare disease diagnosis and management.





### Dr. Allen YU

Founder and Chief Technology Officer  
Codex Genetics Limited

Dr. Allen YU, Ph.D. is a Chevening Scholar 2017/18. He holds a PhD from The Chinese University of Hong Kong (CUHK), and an M.Sc. from Oxford. He is now serving as the founder and Chief Technology Officer of Codex Genetics. With support from ITC, HKSTP, and CUHK, Codex has transformed recent advances in genomics research into clinically actionable insights and provide personalised medicine service through AI and Big Data analytics.



### Professor YU Jun

Director, Institute of Digestive Disease  
The Chinese University of Hong Kong

Professor Jun YU is Choh-Ming Li Professor of Medicine and Therapeutics, Assistant Dean of Faculty of Medicine, Director of Institute of Digestive Disease, Director of State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong. She served as Council Member of American Gastrointestinal Association (AGA) Microbiome & Microbial Therapy (MMT) (2018-2022) and Council Member of AGA Oncology (2017-2018); Vice-Chairman of Cancer and Gut Microbiome of Anti-Cancer Association China; Her research interests being molecular pathogenesis, microbiome, diagnostic biomarkers and therapeutic targets of gastrointestinal cancers and fatty liver disease. She has over 520 peer-reviewed publications (184 papers IF>10; 90 papers with IF>30; ISI citation>26,000, ISI h-index=86).



### Professor Patrick YUNG, MH, JP

Director  
Centre for Neuromusculoskeletal Restorative Medicine

Professor YUNG Shu-Hang Patrick, Chairman of the Department of Orthopaedics and Traumatology, and Assistant Dean (Alumni Affairs), Faculty of Medicine, The Chinese University of Hong Kong, focuses on Orthopaedics sport medicine and arthroscopy surgery.

He serves as the leader for international & local sports medicine centres, e.g. President of the Asian Federation of Sports Medicine (AFSM) and President of the Hong Kong Association of Sports Medicine & Sports Science (HKASMSS). He is also the Director of Hong Kong Centre of Sports Medicine and Sports Science, Hong Kong Jockey Club Sports Medicine and Health Sciences Centre, and Centre of Neuromusculoskeletal Restorative Medicine (CNRM) of InnoHK.



### Professor Benny ZEE

Director, Office of Research and Knowledge Transfer Services  
The Chinese University of Hong Kong

Professor Benny ZEE is the Director of the Office of Research and Knowledge Transfer Services (ORKTS), Professor/Director of the Centre for Clinical Research and Biostatistics, JC School of Public Health and Primary Care, The Chinese University of Hong Kong. Professor ZEE obtained his PhD in Biostatistics from the University of Pittsburgh, USA in 1987. He then joined the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), currently known as Senior Biostatistician. He has a strong interest in various aspects of multi-centre clinical trials, biostatistics and bioinformatics methods, drugs and medical device development, and extensive experience in knowledge transfer activities.

## List of Exhibitors

**Location: Pre-Function Hall, 1/F, Building 10W**



Boston Scientific HK Limited



Codex Genetics Limited



GenieBiome Limited



Johnson & Johnson Innovation



Medtronic Hong Kong Medical Limited



Olympus Hong Kong and China Limited



PHASE Scientific International Limited



Take2 Health Limited





## Location: Atrium Link, G/F, Building 10W



ACT Genomics & Sanomics



Belun Technology Company Limited



Beth Bioinformatics Co., Limited



BioMed Technology Holdings Limited



Center for Neuromusculoskeletal Restorative Medicine



Centre for Novostics



Endovision Limited



Hynovel Biotech Limited



King's Phase Technologies Limited




Microbiota I-Center



Multi-Scale Medical Robotics Center



OAO Limited



SinoMab BioScience Limited



Ynno Med Limited





## Faculty of Medicine The Chinese University of Hong Kong



WWW.MED.CUHK.EDU.HK



CUHKMEDICINE



CUHKMED\_SA



CUHK MEDICINE



CUHK MEDICINE



CU MEDICINE



## Hong Kong Science and Technology Parks Corporation



WWW.HKSTP.ORG



HONGKONGSCIENCEPARK



HKSCIENCEPARK



HKSTP – HONG KONG SCIENCE AND TECHNOLOGY PARKS CORPORATION



HKSTP